Advertisement

Topics

Vaginal Atrophy Atrophic VaginitisAPI Insights, 2017 [Updated: 30052017] Prices from USD $1063

22:23 EDT 19 Jun 2017 | BioPortfolio Report Blog

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

DelveInsight's, Vaginal Atrophy Atrophic Vaginitis API Insights, 2017 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File USDMF and Europe DMF filed by worldwide countries related to the Vaginal Atrophy Atrophic Vaginitis. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales data till 2016.

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
A snapshot of the global Market therapeutics scenario for Vaginal Atrophy Atrophic Vaginitis.
A review of the marketed products under prescription for Vaginal Atrophy Atrophic Vaginitis, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Vaginal Atrophy Atrophic Vaginitis with complete description of mechanism of action, therapeutic class, target, routes of administration and chemical details.
Coverage of API Manufacturers for Vaginal Atrophy Atrophic Vaginitis drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Vaginal Atrophy Atrophic Vaginitis drugs.
Key discontinued Marketed products.
Global Sales Figure from 20122016.Reasons to Buy
Evaluate the marketing status and exclusivity details of Vaginal Atrophy Atrophic Vaginitis key products to exploit opportunities for generic drug development opportunities.
Key players in the pharmaceutical industry.
Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
Design effective counterstrategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Vaginal Atrophy Atrophic Vaginitis.
API intelligence over marketed drugs for Vaginal Atrophy Atrophic Vaginitis and gaining primary intelligence over active ingredients manufacturers across the globe.
Uncovering opportunities in the rapidly growing the US markets.

Original Article: Vaginal Atrophy Atrophic VaginitisAPI Insights, 2017 [Updated: 30052017] Prices from USD $1063

NEXT ARTICLE

More From BioPortfolio on "Vaginal Atrophy Atrophic VaginitisAPI Insights, 2017 [Updated: 30052017] Prices from USD $1063"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...